Laws: Cases and Codes : U.S. Code : Title 22 : Section 2151b-3


   
U.S. Code as of: 01/19/04
Section 2151b-3. Assistance to combat tuberculosis

    (a) Findings
      Congress makes the following findings:
        (1) Congress recognizes the growing international problem of
      tuberculosis and the impact its continued existence has on those
      countries that had previously largely controlled the disease.
        (2) Congress further recognizes that the means exist to control
      and treat tuberculosis through expanded use of the DOTS (Directly
      Observed Treatment Short-course) treatment strategy, including
      DOTS-Plus to address multi-drug resistant tuberculosis, and
      adequate investment in newly created mechanisms to increase
      access to treatment, including the Global Tuberculosis Drug
      Facility established in 2001 pursuant to the Amsterdam
      Declaration to Stop TB and the Global Alliance for TB Drug
      Development.
    (b) Policy
      It is a major objective of the foreign assistance program of the
    United States to control tuberculosis, including the detection of
    at least 70 percent of the cases of infectious tuberculosis, and
    the cure of at least 85 percent of the cases detected, not later
    than December 31, 2005, in those countries classified by the World
    Health Organization as among the highest tuberculosis burden, and
    not later than December 31, 2010, in all countries in which the
    United States Agency for International Development has established
    development programs.
    (c) Authorization
      To carry out this section and consistent with section 2151b(c) of
    this title, the President is authorized to furnish assistance, on
    such terms and conditions as the President may determine, for the
    prevention, treatment, control, and elimination of tuberculosis.
    (d) Coordination
      In carrying out this section, the President shall coordinate with
    the World Health Organization, the Global Fund to Fight AIDS,
    Tuberculosis, and Malaria, and other organizations with respect to
    the development and implementation of a comprehensive tuberculosis
    control program.
    (e) Priority to DOTS coverage
      In furnishing assistance under subsection (c) of this section,
    the President shall give priority to activities that increase
    Directly Observed Treatment Short-course (DOTS) coverage and
    treatment of multi-drug resistant tuberculosis where needed using
    DOTS-Plus, including funding for the Global Tuberculosis Drug
    Facility, the Stop Tuberculosis Partnership, and the Global
    Alliance for TB Drug Development. In order to meet the requirement
    of the preceding sentence, the President should ensure that not
    less than 75 percent of the amount made available to carry out this
    section for a fiscal year should be expended for antituberculosis
    drugs, supplies, direct patient services, and training in diagnosis
    and treatment for Directly Observed Treatment Short-course (DOTS)
    coverage and treatment of multi-drug resistant tuberculosis using
    DOTS-Plus, including substantially increased funding for the Global
    Tuberculosis Drug Facility.
    (f) Definitions
      In this section:
      (1) DOTS
        The term "DOTS" or "Directly Observed Treatment Short-course"
      means the World Health Organization-recommended strategy for
      treating tuberculosis.
      (2) DOTS-Plus
        The term "DOTS-Plus" means a comprehensive tuberculosis
      management strategy that is built upon and works as a supplement
      to the standard DOTS strategy, and which takes into account
      specific issues (such as use of second line anti-tuberculosis
      drugs) that need to be addressed in areas where there is high
      prevalence of multi-drug resistant tuberculosis.
      (3) Global Alliance for Tuberculosis Drug Development
        The term "Global Alliance for Tuberculosis Drug Development"
      means the public-private partnership that brings together leaders
      in health, science, philanthropy, and private industry to devise
      new approaches to tuberculosis and to ensure that new medications
      are available and affordable in high tuberculosis burden
      countries and other affected countries.
      (4) Global Tuberculosis Drug Facility
        The term "Global Tuberculosis Drug Facility (GDF)" means the
      new initiative of the Stop Tuberculosis Partnership to increase
      access to high-quality tuberculosis drugs to facilitate DOTS
      expansion.
      (5) Stop Tuberculosis Partnership
        The term "Stop Tuberculosis Partnership" means the partnership
      of the World Health Organization, donors including the United
      States, high tuberculosis burden countries, multilateral
      agencies, and nongovernmental and technical agencies committed to
      short- and long-term measures required to control and eventually
      eliminate tuberculosis as a public health problem in the world.



Previous [Notes] Next

Related Resources

International Law Guide

International Trade Law Guide

Foreign and International Resources

International Law Discussion

Ads by FindLaw